Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESP Block with Liposomal Bupivacaine for C-Section Analgesia
NCT05664958Phase 4Completed
- Sponsor
- Duke University
- Start
- Apr 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bupivacaine in pain (2 arms), sponsored by Duke University. Primary endpoint: Postoperative Oxycodone Consumption 0-48 Hours After Cesarean Delivery. Started Apr 2023; status: completed.
02
Drugs
bupivacaine
03
Conditions
pain
Beyond the preview
Go deeper on NCT05664958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664958.